Number of pediatric patients with RDEB in the Mission EB study (patients)

Reduction in itch severity for severe disease RDEB patients (percent)

Number of serious adverse events reported for CORDStrom in the Mission EB study (events)

Number of patients enrolled in Phase II AD trial for XPro (patients)

Number of patients treated with INKmune in MDS Phase I trial (patients)

Number of AML patients treated with INKmune in compassionate use (patients)

Number of patients enrolled with INKmune in open label Phase II trial for mCRPC (patients)

Number of company-owned or in-licensed issued patents (patents)

Number of company-owned or in-licensed pending patent applications (applications)

Number of pending patent applications for DN-TNF compositions and formulations (applications)

Number of issued patents for DN-TNF compositions and formulations (patents)

Number of pending patent applications for DN-TNF manufacturing or CMC (applications)

Number of issued patents for DN-TNF manufacturing or CMC (patents)

Number of pending patent applications for use of DN-TNF for treating disease (applications)

Number of issued patents for use of DN-TNF for treating disease (patents)

Number of pending patent applications for INB-16 or INKmune compositions (applications)

Number of issued patents for INB-16 or INKmune compositions (patents)

Number of pending patent applications for use of INKmune for treating disease (applications)

Number of issued patents for use of INKmune for treating disease (patents)

Number of pending patent applications for CORDStrom compositions and formulations (applications)

Number of issued patents for CORDStrom compositions and formulations (patents)

Number of pending patent applications for use of CORDStrom for treating disease (applications)

Number of issued patents for use of CORDStrom for treating disease (patents)

Percent decrease in neurofilament light chain in AD patients receiving XPro (percent)

Percent decrease in phospho Tau in AD patients receiving XPro (percent)

Percent decrease in VILIP in AD patients receiving XPro (percent)

Percent increase in Contactin in AD patients receiving XPro (percent)

Percent decrease in neurogranin in AD patients receiving XPro (percent)

52ca196a8215b109d5fdb33336b1e48d4a4d5040cbdc2fc92faa284dd2c2a0cd

Net Loss (USD, thousands)

Stock-based Compensation (USD, thousands)

Accretion of Debt Discount (USD, thousands)

Research and Development Tax Credit Receivable Changes (USD, thousands)

Other Tax Receivable Changes (USD, thousands)

Prepaid Expenses and Other Current Assets Changes (USD, thousands)

Prepaid Expenses – Related Party Changes (USD, thousands)

Other Assets Changes (USD, thousands)

Accounts Payable and Accrued Liabilities Changes (USD, thousands)

Accounts Payable and Accrued Liabilities – Related Parties Changes (USD, thousands)

Deferred Liabilities Changes (USD, thousands)

Net Cash Used in Operating Activities (USD, thousands)

Net Proceeds from Sale of Common Stock and Warrants (USD, thousands)

Repayments of debt (USD, thousands)

Net cash provided by (used in) financing activities (USD, thousands)

Impact on cash from foreign currency translation (USD, thousands)

NET DECREASE IN CASH AND CASH EQUIVALENTS (USD, thousands)

Cash Paid for Income Taxes (USD, thousands)

Cash Paid for Interest Expense (USD, thousands)

Operating lease liabilities (USD, thousands)

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD (USD, thousands)

CASH AND CASH EQUIVALENTS AT END OF PERIOD (USD, thousands)

508f88482a498dd011ebef514b80e03f14cfbedafd3dff96ac962af82333c165

Revenue (USD, thousands)

General and Administrative Expenses (USD, thousands)

Research and Development Expenses (USD, thousands)

Total Operating Expenses (USD, thousands)

Loss from Operations (USD, thousands)

Other Income (Expense), Net (USD, thousands)

70ff0e570d8efcfe622cb4706b16f7e003fd950c9f2694834c06f634c79bbcf3

Cash and cash equivalents (USD, thousands)

Research and development tax credit receivable (USD, thousands)

Other tax receivable (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

TOTAL CURRENT ASSETS (USD, thousands)

Operating lease – right of use asset (USD, thousands)

Other assets (USD, thousands)

Acquired in-process research and development intangible assets (USD, thousands)

TOTAL ASSETS (USD, thousands)

Accounts payable and accrued liabilities (USD, thousands)

Accounts payable and accrued liabilities – related parties (USD, thousands)

Deferred liabilities (USD, thousands)

Operating lease, current liability (USD, thousands)

TOTAL CURRENT LIABILITIES (USD, thousands)

Long-term operating lease liability (USD, thousands)

TOTAL LIABILITIES (USD, thousands)

Preferred stock (USD, thousands)

Common stock (USD, thousands)

Additional paid-in capital (USD, thousands)

Accumulated other comprehensive loss (USD, thousands)

Accumulated deficit (USD, thousands)

TOTAL STOCKHOLDERS’ EQUITY (USD, thousands)

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (USD, thousands)

d16e7d73e28a7d022c5c5fdb62392ae88be63428b8fe9f5dfd99f68eb3933f3c

INmune Bio Inc (INMB)

Financials